Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

MacroGenics, Inc. (NASDAQ:MGNX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects.

We've discovered 3 warning signs about MacroGenics. View them for free.

Following the upgrade, the consensus from seven analysts covering MacroGenics is for revenues of US$76m in 2025, implying a stressful 51% decline in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$2.07 per share. However, before this estimates update, the consensus had been expecting revenues of US$62m and US$2.57 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.

View our latest analysis for MacroGenics

The consensus price target fell 30%, to US$4.20, suggesting that the analysts remain pessimistic on the company, despite the improved earnings and revenue outlook.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 61% annualised revenue decline to the end of 2025. That is a notable change from historical growth of 7.1% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 17% per year. It's pretty clear that MacroGenics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting MacroGenics is moving incrementally towards profitability. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. A lower price target is not intuitively what we would expect from a company whose business prospects are improving - at least judging by these forecasts - but if the underlying fundamentals are strong, MacroGenics could be one for the watch list.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple MacroGenics analysts - going out to 2027, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.